What We Measure, and When It Publishes
What MindScape Retreat's SSRI discontinuation protocol measures, and when the numbers publish. Every guest is scored on the DESS and the PHQ-9 from baseline through 90-day follow-up; cohort aggregates publish at mindscaperetreat.com/outcomes once at least 20 people hold paired data.
Study Overview
Trapped on Antidepressants. A Supervised Way Off.
MindScape Retreat treats people who have been unable to discontinue SSRI or SNRI antidepressants because of severe discontinuation syndrome. Nearly everyone who arrives has already made at least one attempt at conventional tapering under physician supervision, with intolerable withdrawal symptoms driving a return to the medication.
Most have been on the medication for years, not months. Withdrawal severity is quantified on the Discontinuation Emergent Signs and Symptoms (DESS) checklist, scored 0 to 60, and depression burden on the PHQ-9, scored 0 to 27, so the underlying depressive disorder that drove the original prescription is tracked separately from the withdrawal syndrome.
The 10 to 14 day protocol combines supervised medication tapering with strategically timed ibogaine administration, serotonergic support protocols, and intensive integration therapy. Outcomes are tracked at Days 5 and 12, then again at 30 and 90 days post-treatment. Structured collection began in July 2026; cohort aggregates publish at mindscaperetreat.com/outcomes once at least 20 people hold paired baseline and follow-up data, never before.
The live analytics dashboard below tracks three parallel trajectories across the 10 to 14 day protocol: DESS withdrawal severity, PHQ-9 depression burden, and a serotonin function proxy that estimates receptor density normalization over time. SSRI discontinuation syndrome is assessed primarily via the DESS (Discontinuation-Emergent Signs and Symptoms) checklist, the validated instrument that captures the characteristic constellation of withdrawal features including brain zaps, dizziness, electric shock sensations, irritability, insomnia, vivid dreams, paresthesia, and emotional lability. Guests who arrive scoring in the severe DESS range are not having mild or self-resolving withdrawal reactions; they are carrying entrenched neuroadaptive responses that require active pharmacological intervention rather than patience.
Tracking DESS alongside PHQ-9 is methodologically important: it allows the clinical team to differentiate between true discontinuation symptoms and underlying condition relapse. When PHQ-9 rises independently of DESS, it signals that the patient's depressive disorder, not withdrawal, is re-emerging, requiring a different therapeutic response. Scoring both daily is what makes that distinction visible at the bedside instead of in hindsight, and it is the only way ibogaine's two proposed actions, serotonergic bridging and neuroplastic recalibration, can be told apart at all.
DESS is the metric expected to move first, and the 48 to 72 hours following ibogaine administration is the window in which that change would appear. The reason is pharmacological: ibogaine facilitates serotonin transporter resensitization and normalizes receptor density inside the acute treatment window, providing the neurobiological “bridge” that conventional tapering strategies attempt but pharmacologically cannot deliver. The speed of DESS reduction distinguishes ibogaine's mechanism from both slow-taper protocols and bridge medications like fluoxetine substitution, which typically require weeks to produce comparable symptom reduction.
PHQ-9 is tracked in parallel for an equally important reason: a protocol that only suppressed withdrawal would leave the underlying depressive pathology untouched. Ibogaine is proposed to act on both at once rather than masking withdrawal with a substitute serotonergic compound, and scoring both instruments is how that claim gets tested rather than asserted. This dual-pathway action reflects ibogaine's ability to modulate serotonin transporter function while simultaneously promoting BDNF-driven neuroplasticity and default mode network reorganization, the same mechanisms responsible for its antidepressant effects in non-SSRI-dependent populations.
Three measures carry the clinical weight across this protocol: the DESS withdrawal score, a serotonin function proxy, and the PHQ-9 depression severity index. The DESS, scored 0 to 60 on the full checklist, is the clinical field's primary instrument for quantifying SSRI discontinuation syndrome severity, and a score below 10 is generally considered clinically insignificant. The serotonin function proxy (scaled 0 to 10) estimates the relative normalization of serotonergic receptor density and transporter availability, a surrogate biomarker for the neurobiological recovery process that standard clinical instruments cannot directly capture.
Reading the three together is what makes the logic of ibogaine's proposed action testable: if serotonergic recalibration is real, serotonin function should normalize upward while withdrawal severity (DESS) and depressive burden (PHQ-9) fall in parallel. That is the hypothesis this protocol is built to check, which is why all three are scored at the same timepoints rather than selectively.
What separates this protocol from a slow taper is not speed alone but mechanism. Conventional slow tapers produce gradual symptom reduction by incrementally shrinking the withdrawal signal, whereas ibogaine is proposed to resolve the neurobiological condition generating that signal by restoring serotonergic homeostasis from the receptor level upward. The distinction matters because the goal is not a guest who is “managing” ongoing withdrawal but one who is neurobiologically no longer in it, and the DESS checklist is scored daily precisely so that difference is documented rather than assumed.
The serotonin function proxy exists to carry the mechanistic correlate: ibogaine's serotonergic activity provides a “soft landing” that bridges the gap between chronic SSRI-driven receptor downregulation and natural serotonin system homeostasis. For guests who have spent years with pharmacologically elevated synaptic serotonin, the aim is receptor sensitivity and transporter function restored toward baseline without the months of dysregulation that unassisted discontinuation would entail. Cohort aggregates publish at mindscaperetreat.com/outcomes once at least 20 people hold paired data, never before.
Mechanism of Action
How Ibogaine Resolves Antidepressant Discontinuation Syndrome
SSRI discontinuation syndrome arises from the abrupt reduction of serotonergic input that the brain's receptor systems have adapted to over months or years of antidepressant use. The characteristic symptoms, including electric shock sensations ('brain zaps'), profound dizziness, nausea, emotional lability, and cognitive disruption, reflect serotonergic receptor hypersensitivity following drug withdrawal.
Ibogaine's mechanism in SSRI discontinuation operates through two primary pathways. First, ibogaine acts as a potent serotonin reuptake inhibitor in its own right, providing a bridge of serotonergic support during the withdrawal period that blunts the severity of discontinuation symptoms. Second, ibogaine's neuroplasticity-promoting effects, particularly BDNF upregulation, support rapid receptor recalibration, compressing what might otherwise take months into a period of days.
The result is not simply a symptom-suppressing workaround but a genuine neurobiological reset of the serotonergic system. Patients who complete the MindScape protocol do not taper from ibogaine onto another antidepressant: they emerge with a recalibrated serotonin system, and most describe a mood baseline better than the one the medication had been maintaining, which reflects an antidepressant action belonging to the ibogaine treatment itself.
Clinical Protocol
10 to 14 Day SSRI Discontinuation Protocol
Psychiatric & Medication Assessment
Full psychiatric evaluation including current diagnosis, medication history, prior discontinuation attempts, withdrawal symptom history, and current PHQ-9 and DESS baseline scores. We identify the specific SSRI or SNRI, current dose, and duration of use to design the optimal tapering and ibogaine timing protocol.
Medical Screening & Cardiac Clearance
Bloodwork, EKG, and cardiovascular evaluation. Because patients arrive on active antidepressant medication, particular attention is paid to serotonergic drug interaction risks. Our protocol includes a mandatory pre-treatment clearance window to ensure safe ibogaine administration.
Onsite TA Booster Taper (Days 1 to 5)
From day one, twice-daily ibogaine TA (total alkaloid) booster doses are administered under physician supervision while the SSRI or SNRI dose is reduced according to a personalized schedule. The TA boosters provide graduated serotonergic bridging that pharmacologically prevents serotonin syndrome and blunts discontinuation symptoms in real time. Continuous cardiac telemetry, daily DESS scoring, and 24/7 nursing presence allow step size and pace to be calibrated to each patient's response, never to a calendar.
HCl Flood Dose (Days 5 to 7)
Once the SSRI or SNRI has been titrated to the protocol-defined safe threshold and noribogaine has been pre-loading from the booster phase, the HCl flood dose is administered under continuous physician and nursing supervision with telemetry-grade cardiac monitoring throughout. The flood dose drives the deeper neuroplastic reset and antidepressant effect; the booster phase has already neutralized the discontinuation syndrome that traditionally derails this transition.
Recovery & Integration (Days 8 to 12)
Post-ibogaine recovery focuses on stabilization, integration therapy, and daily DESS reassessment. The majority of patients report dramatic withdrawal symptom reduction within 48 to 72 hours of ibogaine administration. The final days consolidate neurobiological gains with structured therapeutic support.
30-Day Follow-Up & Ongoing Support
Patients are reassessed at 30 and 90 days post-treatment for DESS scores, PHQ-9, and overall wellbeing, so the trajectory is recorded rather than recalled. Those with significant underlying depression are connected with integration-trained therapists. Needing medication again is not treated as a failure; that call is made clinically with our team rather than by default.
Frequently Asked Questions
Questions About Ibogaine for SSRI Discontinuation
Every MindScape treatment program includes a guided 5-MeO-DMT (Bufo) ceremony, part of the all-inclusive price, not an add-on.